2025 Hyundai Inster Cross review
The range-topping version of the Inster is a $45,000 plus on-roads proposition, meaning you're going to be shelling out more than $50K to get this minute commuter into your driveway.
While it might have cutesy design and cool cleverness inside, that's a huge price for something so small. You could choose any number of more practical SUVs for similar money, or less – the MG S5EV stands out, or the BYD Atto 3.
But if you're drawn to the design (understandable) and can work within the parameters of this car (questionable), it could be a delight to live with.
The Cross version has a heap of great spec and tech, including heated and ventilated front seats, a heated steering wheel, climate control with a heat pump, and even vehicle-to-load charging, which can allow you to power appliances using the car's battery.
It's not the biggest battery in the class, with a claimed driving range of 360km for the Cross model with the sunroof. There's also a version with a roof basket that has just 293km of range.
But unlike some cheaper EV rivals, this one has fast charging on its side. The AC rate is up to 10.5kW, meaning recharges in about 4 hours using three-phase power. Public charging capability is good too, with 120kW charging speeds meaning you should be able to get from 10-80% in 30 mins.
It's a zippy, urgent feeling thing to drive thanks to instant torque. It pulls away from traffic lights and slips into traffic gaps with ease, and the Cross model gets a clever urban-friendly inclusions like a surround-view camera system and a blind-spot camera display, too.
But some of the safety tech is, frankly, shitful. There's a driver monitoring camera system which incessantly chimes at you when you're using any of the screen tech, while the speed sign recognition and warning system is painful. You can turn those things off if you're chime-triggered like me, but it's tedious to do each time you get back in the car. (And yes, there is a mute button to shut the overspeed warning up, but the car will still chime to tell you that you've entered a new speed zone… sometimes even if you haven't!)
While it drives great at pace and in town over bumps and lumps, be mindful that it can feel a bit bigger than it is when you're trying to do a speedy U-turn or parking in a tight spot, as the steering weights up at low speeds, and its long-ish wheelbase means it doesn't have the smallest turning circle for such a little car.
Now, it is little, and it's only a four-seater. Plus there's no spare wheel.
But if you're okay with that, there's a clever sliding second-row bench system, and in the Cross you can flatten the seats so you can camp inside… if you're small.
The cabin design is lovely though, especially with the Dark Grey + Amazonas Khaki interior trim – no cost with some exterior colours, and speaking of which, the Amazonas Matte Green paint is a $1000 extra.
And while the tech is decent (thankfully, there are lots of buttons!), the media system doesn't include wireless smartphone mirroring. So you gotta plug in, and you have to keep a cable sitting messily in front of the passenger.
Otherwise though, there's reasonable cabin cleverness, aside from the cupholders - which are integrated into the front 'not-actually-a-bench' seat. You won't want to bump your coffee down there!
Look, this is an interesting thing, but more of a novelty than an actually convincing electric car option for a pragmatic customer.
All bark, no bite, then?
3.0 stars
Hyundai Inster Cross
BATTERY: 49kWh NMC
ENERGY CONSUMPTION: 15.1kWh per 100km claim, 15.5kWh per 100km on test
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
2 hours ago
- News.com.au
ASX biotechs join global race for cell therapy breakthroughs
ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to 'break new ground' in treatment of solid tumours with CAR-T and NK cell assets Cell therapies represent a promising frontier in modern medicine, offering potential to treat, and in some cases cure diseases previously considered untreatable. By using living cells, either from the patient (autologous) or a donor (allogeneic), cell therapies aim to repair, replace, or enhance biological functions within the body. Originally pioneered for blood cancers through technologies like chimeric antigen receptor (CAR) T-cell therapies, the field is rapidly expanding into solid tumours, autoimmune conditions, and neurological diseases. Australia has close ties to CAR T-cell therapy development. Melbourne-based Cell Therapies Pty Ltd, the country's largest Therapeutic Goods Administration (TGA) licensed cell and gene therapy manufacturer, was the commercial production partner for Novartis's Kymriah – the first CAR T-cell therapy approved by the US Food and Drug Administration (FDA) in 2017. While the science remains complex, advances in manufacturing, engineering, and clinical design are making next-generation cell therapies more accessible and scalable, positioning them as a key pillar of future healthcare. Several ASX biotechs are positioning themselves at the forefront of cell therapies to capture a share of the global market, which accounted for ~US$6.04 billion in 2024 and is anticipated to close in on US$48bn by 2034, growing at a CAGR of almost 23%. In particular focus here is the treatment of solid tumours, which account for 90% of all cancers but have so far proven difficult to treat with cell therapies. Arovella in rare biotech club targeting CAR-iNKT therapies Arovella Therapeutics (ASX:ALA) is the only ASX-listed biotech delving into CAR Invariant Natural Killer T-cells (iNKT) therapies, and one of only a few globally. CEO Dr Michael Baker told Stockhead iNKT cells were distinct from the more familiar natural killer, or NK cells, which along with T-cells had limitations. T-cells can't be used off-the-shelf unless they are genetically engineered. While NK cells can quickly eliminate abnormal cells such as tumour cells, iNKT cells go further. Not only do they kill like T and NK cells, but they also trigger a longer-lasting response by activating other key parts of the immune system. Because iNKT cells recognise foreign threats differently – unlike classic CAR-T cells – it has been shown in clinical trials that iNKT cells do not cause complications like graft-versus-host disease (GvHD) when administered from a healthy donor to a patient. The FDA has approved seven CAR-T therapies to date, all for blood cancers, but no iNKT treatments. While over 120 global trials are investigating CAR-NK therapies for blood and solid tumours, CAR iNKT research remains limited. Baker said most cell therapies use the patient's own cells (autologous), but this was costly, slow, and relies on compromised cells. Arovella is taking an allogeneic approach, using healthy donor cells to create off-the-shelf, frozen doses shipped to clinics as needed in a 'ready-to-use' model. Its lead therapeutic ALA-101 combines iNKT cells with a CAR that targets CD19, a protein commonly found on B-cell blood cancers like lymphoma and leukaemia. One of Arovella's next key milestones is to apply to the FDA for its first-in-human trial, enrolling non-Hodgkin's lymphoma and leukaemia patients. The company's other key goal is also tackling solid tumours. "The first approved blood cancer targeting CAR-T products have demonstrated just how important cell therapies will be for cancer treatment," Baker said. "We look forward to using our CAR-iNKT cell platform to expand upon that work and aim to create products capable of increasing access and reducing costs. "There is a lot of great science that will continue to advance the off-the-shelf cell therapy sector. "That is why we continue to scour the globe for new IP to build into our CAR-iNKT platform, to either strengthen our CAR-iNKT cells or to broaden the cancer types that we can target.' Imugene also aims to crack solid tumours Imugene (ASX:IMU) is developing cell-based immunotherapies, including allogeneic CAR T-cell therapies, oncolytic viruses and B-cell vaccines, to address both blood cancers and solid tumours. The company's lead cell therapy candidate azercabtagene zapreleucel (azer-cel) is an off-the-shelf CAR T-cell therapy targeting CD19, a protein commonly expressed on malignant B-cells. There are no allogeneic (off the shelf) CAR T therapies approved to date. Azer-cel is currently undergoing clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a hard-to-treat form of non-Hodgkin's lymphoma. In early-phase studies, azer-cel has demonstrated promising results, including high complete response rates and durable remissions in patients who have previously relapsed after autologous CAR T-cell therapies. "We are very pleased with the continued positive data coming from the azer-cel trial, which further reinforces its potential as a treatment for lymphoma patients who have failed on several previous therapies including auto CAR T," CEO and managing director Leslie Chong told Stockhead. Imugene's next-generation cell therapy platform OnCARlytics is designed to help overcome one of the biggest challenges in cancer treatment, making solid tumours visible to the immune system. The approach combines Imugene's proprietary CF33 oncolytic virus, which selectively infects and destroys cancer cells, with CD19-targeting CAR T-cells. The CF33 infects tumour cells and forces them to express CD19, a marker typically found on blood cancer cells but absent on solid tumours. By introducing CD19 into the tumour environment, the therapy effectively tags the cancer, allowing CD19-specific CAR T-cells to recognise and attack the tumour. Imugene's pipeline also includes multiple immunotherapy B-cell vaccine candidates, which involve inducing the body to produce polyclonal antibodies against specific tumour-associated antigens. The company's PD1-Vaxx is designed to generate antibodies that block the PD-1 receptor, potentially mimicking the effects of checkpoint inhibitors such as pembrolizumab (Keytruda). The company recently announced the first patient had been dosed in Australia as part of an investigator-sponsored Phase II Neo-POLEM clinical trial, which is evaluating PD1-Vaxx's potential to improve treatment outcomes for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-high) colorectal cancer. This aggressive cancer subtype accounts for ~15% of all colorectal cancer cases. Chimeric advances cell therapy assets in solid tumours Chimeric Therapeutics (ASX:CHM) has three CAR T and NK cell assets in clinical trials. It has an ongoing phase 1/2 clinical trial for its novel CHM CDH17 CAR T-cell therapy targeting advanced colorectal cancer and Neuroendocrine tumours of the midgut. Their second program CHM CLTX CAR T is in a phase 1B clinical trial in recurrent/progressive glioblastoma, a form of brain cancer. CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial, demonstrated safety and efficacy in blood cancers and solid tumours. Two additional Phase 1B clinical trials investigating CHM CORE-NK in combination regimens have been initiated in Acute Myeloid Leukemia (AML). "We're excited to be actively advancing in the clinic and pushing through dose levels as we break new ground in the solid tumour CAR T-cell therapy space," CEO Dr Rebecca McQualter told Stockhead. Prescient advancing cell therapy platforms While predominately focused on PTX-100, its first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1), Prescient Therapeutics (ASX:PTX) is also advancing its proprietary OmniCAR and CellPryme platforms. OmniCar has potential to allow CAR T therapy cells to be more targeted, safer, more effective, cost-effective and of longer duration. CellPryme is a complementary application to OmniCar split into two components. CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control. Meanwhile, CellPryme-A acts as an adjuvant therapy, increasing the expansion of CAR T-cells and enhancing their ability to penetrate the tumour. AdAlta adopts East to West cellular immunotherapy strategy AdAlta (ASX:1AD) and venture capital firm SYNthesis BioVentures Fund (SYNBV) launched AdCella in 2024 to adopt an East to West strategy and bring cutting-edge cellular immunotherapies from Asia, particularly China, into Western markets. SYNBV was co-founded by Professor Andrew Wilks, who alongside Amplia (ASX:ATX) CEO Dr Chris Burns received the 2024 Prime Minister's Prize for Innovation for co-inventing momelotinib, an FDA-approved treatment for myelofibrosis. The strategy leverages AdAlta managing director and CEO Dr Tim Oldham's deep expertise in cellular immunotherapies and extensive operational experience in Asia to identify and advance promising Asian cellular therapies that can be transitioned into regulated western markets. Oldham was previously CEO of Cell Therapies and said he'd been fortunate to witness firsthand the rapid evolution of China's biotech sector and remarkable progress in cellular immunotherapies for cancer treatment over the past 15 years. The East to West cellular immunotherapy strategy for cancer is now a core growth priority for AdAlta and a key driver of future pipeline growth and value creation.

News.com.au
2 hours ago
- News.com.au
Amazon Prime Day 2025: Best headphone deals in Australia
Tired of earbuds that vanished months ago or headphones that can't commit to playing a full song without cutting out? Same. Thankfully, Amazon Prime Day is back (on until July 14) and with it comes a stack of seriously good audio deals. Right now, you can score a massive 58 per cent off Sennheiser's Momentum 4, now $265 (down from $625). One reviewer labelled them 'superb headphones' with 'amazing sound quality'. 'Grabbed these monsters for $300. I reckon no one can beat the quality with that price. It's just a different level,' another praised. Also worth snapping up? Bose QuietComfort Ultra is also on sale for 40 per cent off, plunging to $389 (down from $649). I actually own these and love the sound quality and how well it blocks out unwanted noise. Plus, they're comfortable enough to wear for long periods (even if you're a fellow eyeglass wearer). Keep in mind these are Prime member exclusive deals. If you're not a member yet, it's worth signing up – it's $9.99 per month and gives you access to free shipping, Prime Video, music, and these major discounts. Items are in stock and prices are accurate at time of publishing, but stock moves fast so if you spot something you love, don't wait to snap it up. In this article Shop more headphones deals at Amazon Australia. BEST PRIME DAY BOSE HEADPHONES DEALS Shop more Bose headphones deals at Amazon Australia. BEST PRIME DAY SONY HEADPHONES DEALS Shop more Sony headphones deals at Amazon Australia. 24 per cent off Apple AirPods 4, $166 (down from $219) 16 per cent off Apple AirPods 4 with Active Noise Cancellation, $251 (down from $299) 6 per cent off Apple AirPods Max (Purple), $845 (down from $899) 6 per cent off Apple AirPods Max (Blue), $845.90 (down from $899) Shop more headphones deals at Amazon Australia. BEST PRIME DAY BEATS HEADPHONES DEALS 14 per cent off Beats Solo 4, $239 (down from $277.95) Shop more Beats headphones deals at Amazon Australia. Shop more gaming headphones deals at Amazon Australia. BEST PRIME DAY OVER-EAR HEADPHONES DEALS Shop more headphones deals at Amazon Australia. BEST PRIME DAY WIRELESS HEADPHONES DEALS BEST PRIME DAY SPEAKER AND HOME AUDIO DEALS Shop more speaker deals at Amazon Australia. When is Amazon Prime Day? This year, Amazon Prime Day will run from Tuesday, July 8 at AEST through to Monday, July 14. What is Amazon Prime Day? Amazon Prime Day is an annual shopping event run exclusively for Amazon Prime members. Despite its name, Prime Day runs over several days, giving members plenty of opportunity to snap up discounts on everything from fashion and electronics to home appliances and essential groceries. Both local and international deals are available through the Amazon Australia site, with international deals typically kicking off once the Australian sale has ended. Do you need a membership to shop Amazon Prime Day deals? Yes, Amazon Prime Day deals are exclusive to Amazon Prime members. If you aren't already a member, you can sign up now for a 30-day free trial. Amazon Prime membership explained As well as granting you access to the Amazon Prime Day sales and other member-only deals throughout the year, Amazon Prime comes with plenty of other benefits. Membership includes fast and free delivery on millions of eligible items, free international delivery from the Amazon Global Store with no minium spend. You also get a selection of free games every month and a Twitch Channel subscription with Prime Gaming, a rotating selection of books and more with Prime Reading, ad-free music streaming with Amazon Prime Music and a great range of movies and TV shows with Prime Video. You can also get bonus credits to spend on any audiobook with an Audible membership. Amazon Prime membership costs $9.99 per month, and comes with a 30-day free trial period. There's also currently a limited time offer which brings the cost down to just $0.99 for the first three months. Sign up for an Amazon Prime membership. Looking for more great bargains? Sign up to our checkout shopping newsletter to be kept in the loop about great products and upcoming sales.

News.com.au
13 hours ago
- News.com.au
Recalled Anker power banks could ‘catch fire', safety watchdog warns
Consumers have been warned to stop using a range of power banks immediately amid fears they could overheat and catch fire. Four models of Anker power banks, which were sold on Amazon, eBay and the Anker website, have been recalled by the Australian Competition and Consumer Commission's product safety watchdog. Incidents of the power banks catching alight have happened overseas and caused property damage. More than one million Anker power banks have been recalled internationally. Consumers were warned of the risk of serious burn injuries that could occur if their device was to overheat and catch fire. The portable electronic charging devices were sold for more than a year throughout the country, and internationally. The affected power banks were sold from 1 December 2023 to 13 June 2025. The models include the Anker Power Bank (10K, 22.5W), Anker Power Bank (20,000mAh, 22.5W, built in USB-C cable), Anker Zolo Power Bank (20K, 30W, built USB-C and Lightning cable) and the Anker Zolo Power Bank (20K, 30W, built in USB-C cable). Anyone who had bought the devices was advised to stop using them immediately. Consumers can check their powerbank's serial number on the Anker website to determine if they are affected, and register for a replacement. The power banks will then need to be disposed of safely.